Fusion Antibodies PLC (FAB)

London

Currency in GBP

13.50

-0.25(-1.82%)

Closed·10/10

Fair Value

Unlock Value

Day's Range

12.50

15.00

52 wk Range

3.81

21.00

FAB Financial Summary

A brief financial summary of Fusion Antibodies PLC as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio-10.35

Price/Book29.01

Debt / Equity2.99%

Return on Equity-139.16%

Dividend Yield0.00%

EBITDA-1.62M

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2016

31/03

2017

31/03

2018

31/03

2019

31/03

2020

31/03

2021

31/03

2022

31/03

2023

31/03

2024

31/03

2025

31/03

Income Statement

Total Revenues

aa.aa

4.17

4.8

2.9

1.14

1.97

Gross Profit

aa.aa

2.02

2.47

0.57

-0.05

0.43

Operating Income

aa.aa

-1.25

-1.33

-2.89

-2.27

-1.73

Net Income

aa.aa

-2.9

-1.2

-2.6

-2.23

-1.71

Balance Sheet

Total Assets

aa.aa

5.83

4.92

2.06

2.42

1.32

Total Current Liabilities

aa.aa

1.21

0.88

0.58

0.62

Total Equity

aa.aa

4.75

3.68

1.12

1.79

0.67

Cash Flow

Levered Free Cash Flow

aa.aa

-1.17

-0.22

-1.08

-0.97

-0.75

Cash from Operations

aa.aa

-1.14

-0.33

-1.75

-1.77

-1.36

Cash from Investing

aa.aa

-0.36

-0.26

-0.11

-0.01

Cash from Financing

aa.aa

2.65

-0.06

2.77

0.53

Net Change in Cash

aa.aa

1.15

-0.64

-1.85

-0.84

* In Millions of GBP (except for per share items)

Earnings

Latest Release

Sep 04, 2025

EPS / Forecast

-0.01 / --

Revenue / Forecast

758.00K / 800.00K

EPS Revisions

Unlock

Last 90 days

FAQ

What were Fusion Antibodies's earnings for the latest quarter?

The Fusion Antibodies EPS (TTM) is -0.02. Fusion Antibodies reported sales of 0.76, net income of -0.96, and EPS of -0.01 for the latest quarter.

What was Fusion Antibodies's net income for the latest quarter?

Fusion Antibodies's net income for the latest quarter was -0.96.

How did Fusion Antibodies's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1.21 in the previous quarter to 0.76 in the latest quarter, and net income moved from -0.76 to -0.96 compared to the previous quarter.

What is Fusion Antibodies's net profit margin on a TTM basis?

Fusion Antibodies's trailing twelve months (TTM) net profit margin is -87.18%.

How does Fusion Antibodies's debt to equity ratio compare to industry standards?

Fusion Antibodies's total debt-to-equity ratio is 2.99%.

What is Fusion Antibodies's return on investment on a TTM basis?

Fusion Antibodies's trailing twelve months (TTM) return on investment (ROI) is -139.16%.

Did Fusion Antibodies gain or lose cash last quarter?

In the latest quarter, Fusion Antibodies's net change in cash was -0.08 million.

What were Fusion Antibodies's total assets and liabilities in the latest quarter?

As of the latest quarter, Fusion Antibodies reported total assets of 1.32 million and total liabilities of 0.62 million.

How has Fusion Antibodies's total revenue grown this year?

Fusion Antibodies's total revenue was 1.21 in the previous quarter and 0.76 in the latest quarter.

What is Fusion Antibodies's gross margin on a TTM basis?

Fusion Antibodies's trailing twelve months (TTM) gross margin is 21.88%.

What was Fusion Antibodies's revenue per share for the latest quarter?

Fusion Antibodies's revenue per share for the latest quarter was 50.74.

NSE 30

5,362.52

+30.44

+0.57%

NSE All Share

146,988.05

+783.73

+0.54%

US 30

45,255.50

-1,102.9

-2.38%

US 500

6,510.80

-224.3

-3.33%

FTSE 100

9,427.47

-81.93

-0.86%

DAX

24,241.46

-369.79

-1.50%

South Africa Top 40

102,649.81

-423.73

-0.41%

Market Movers

Name	Last	Chg. %	Vol.
Fidelitybk	20.300	-0.98%	47.34M
Zenith Bank	68.50	-1.01%	18.22M
Lafarge Africa	129.95	+0.23%	3.96M
Dangote Cement	575.00	+6.48%	2.02M
Aradel Holdings	628.00	-0.29%	1.42M
MTN Nigeria	471.00	0.00%	964.68K
Seplat Petroleum	5,917.20	0.00%	214.91K

Name	Last	Chg. %	Vol.
Dangote Cement	575.00	+6.48%	2.02M
Nem	29.150	+5.23%	240.50K
Jaiz Bank	4.50	+4.65%	9.42M
FTN Cocoa Processors PLC	5.80	+3.57%	1.90M
CWG	17.950	+3.46%	1.16M
Deap Capital Management Trust	1.80	+3.45%	3.63M
UPDC	6.60	+3.13%	2.43M

Name	Last	Chg. %	Vol.
UH REIT	51.85	-9.98%	317.32K
Meyer	15.10	-9.85%	979.81K
Sterling Bank	7.550	-9.58%	16.71M
Cornerst	6.21	-6.90%	739.38K
Etranz	15.000	-6.25%	478.91K
Neimeth	6.01	-6.09%	654.75K
Transcorp	46.100	-5.92%	823.36K

Trending Stocks

Name	Last	Chg. %	Vol.
Honeywell Flour Mills Plc	23.000	0.00%	663.97K
Chams	4.30	+0.23%	38.45M
UBA	42.80	+1.30%	10.39M
Zenith Bank	68.50	-1.01%	18.22M
Dangote Cement	575.00	+6.48%	2.02M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaa Aaaaaaa A	5,917.20	+50.97%	8,933.20
Aaaaaaaaaaaaaaaaa Aa	1,870.00	+31.35%	2,456.24
Aaaaa Aaaa Aaaa	38.15	+28.36%	48.97
Aaaaaaaaaaaaaa Aaaa	575.00	+27.30%	731.98
Aaaaaaaaaaaaa	159.00	+20.61%	191.77
Aa Aaaaa A A Aaaaaa	70.00	+20.33%	84.23
Aaaaaaaaaa	640.00	+11.07%	710.85

Name	Last	Upside	Fair Value
Aaaa Aaaaaaa A	5,917.20	+50.97%	8,933.20
Aaaaaaaaaaaaaaaaa Aa	1,870.00	+31.35%	2,456.24
Aaaaa Aaaa Aaaa	38.15	+28.36%	48.97
Aaaaaaaaaaaaaa Aaaa	575.00	+27.30%	731.98
Aaaaaaaaaaaaa	159.00	+20.61%	191.77
Aa Aaaaa A A Aaaaaa	70.00	+20.33%	84.23
Aaaaaaaaaa	640.00	+11.07%	710.85

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Fusion Antibodies PLC (FAB)

FAB Financial Summary

Key Ratios

Statements Highlights

Earnings

FAQ

What were Fusion Antibodies's earnings for the latest quarter?

What was Fusion Antibodies's net income for the latest quarter?

How did Fusion Antibodies's performance compare year-over-year in the latest quarter?

What is Fusion Antibodies's net profit margin on a TTM basis?

How does Fusion Antibodies's debt to equity ratio compare to industry standards?

What is Fusion Antibodies's return on investment on a TTM basis?

Did Fusion Antibodies gain or lose cash last quarter?

What were Fusion Antibodies's total assets and liabilities in the latest quarter?

How has Fusion Antibodies's total revenue grown this year?

What is Fusion Antibodies's gross margin on a TTM basis?

What was Fusion Antibodies's revenue per share for the latest quarter?

Trending Stocks